OTCMKTS:MLLCF - Molecular Partners Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$23.85
▲ +0.215 (0.91%)
1 month | 3 months | 12 months
Get New Molecular Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MLLCF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MLLCF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $23.85.
Hold
The current consensus among 5 investment analysts is to hold stock in Molecular Partners. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/19/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
10/30/2020Credit Suisse GroupReiterated RatingNeutral
i
10/7/2020CSFBReiterated RatingNeutral
i
10/7/2020Credit Suisse GroupReiterated RatingNeutral
i
8/12/2020HC WainwrightReiterated RatingBuy
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/8/2020HC WainwrightReiterated RatingBuy
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/2/2020HC WainwrightInitiated CoverageBuy
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/1/2020Royal Bank of CanadaReiterated RatingBuy
i
(Data available from 11/27/2015 forward)
Molecular Partners logo
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Read More

Today's Range

Now: $23.85
$23.64
$24.00

50 Day Range

MA: $20.58
$16.50
$24.56

52 Week Range

Now: $23.85
$16.00
$28.00

Volume

908 shs

Average Volume

12,422 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A